Skip to content

Study · Randomized controlled trial · 2019

4 results

Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.

Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A

Diabetes, obesity & metabolism25 Oct 2018Cited by 28 (Europe PMC)

PMID30260088 (opens in a new tab)PMCIDPMC6587748 (opens in a new tab)DOI10.1111/dom.13547 (opens in a new tab)PepBankPUB-30260088
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes in the LEADER trial, EQ-5D utility index score deteriorated less with liraglutide than with placebo at 36 months.

    In plain wordsIn people with type 2 diabetes, self-rated health declined less with liraglutide than with placebo over 36 months.

    Peptide
    Liraglutide
    Outcome
    IncreaseEQ-5D utility index score change at 36 months
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Source sentences

    Summary
    At 36 months, less deterioration in EQ-5D utility index score was seen in the liraglutide group (-0.058) than in the placebo group (-0.082; estimated treatment difference [ETD] 0.023, 95% confidence interval [CI] 0.004;0.043; P = 0.020).
    2 context sentences
    Summary · context
    The EQ-5D was administered every 12 months in a subset of patients from Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, the United Kingdom and the United States.
    Summary · context
    We compared changes in utility index scores and visual analogue scale (VAS) scores from baseline to 36 months in participants treated with liraglutide and placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes in the LEADER trial, EQ-5D VAS score decreased less with liraglutide than with placebo.

    In plain wordsIn people with type 2 diabetes, self-rated health on a visual scale fell less with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseEQ-5D VAS score change at 36 months
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Source sentences

    Summary
    A smaller decrease in EQ-5D VAS score was also demonstrated in the liraglutide group (-3.51) vs. the placebo group (-5.45; ETD 1.94, 95% CI 0.32;3.57; P = 0.019).
    2 context sentences
    Summary · context
    The EQ-5D was administered every 12 months in a subset of patients from Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, the United Kingdom and the United States.
    Summary · context
    We compared changes in utility index scores and visual analogue scale (VAS) scores from baseline to 36 months in participants treated with liraglutide and placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes in the LEADER trial, the benefit of liraglutide over placebo was driven primarily by shifts in the mobility and self-care domains.

    In plain wordsIn people with type 2 diabetes, liraglutide's benefit over placebo in self-rated health came mainly from better mobility.

    Peptide
    Liraglutide
    Outcome
    IncreaseEQ-5D mobility domain
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Source sentences

    Summary
    The benefits of liraglutide treatment compared with placebo were driven primarily by shifts in the domains of mobility and self-care.
    2 context sentences
    Summary · context
    The EQ-5D was administered every 12 months in a subset of patients from Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, the United Kingdom and the United States.
    Summary · context
    We compared changes in utility index scores and visual analogue scale (VAS) scores from baseline to 36 months in participants treated with liraglutide and placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In people with type 2 diabetes in the LEADER trial, the benefit of liraglutide over placebo was driven primarily by shifts in the self-care and mobility domains.

    In plain wordsIn people with type 2 diabetes, liraglutide's benefit over placebo in self-rated health came mainly from better self-care.

    Peptide
    Liraglutide
    Outcome
    IncreaseEQ-5D self-care domain
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · 36 monthsAs given in this study (human).

    Source sentences

    Summary
    The benefits of liraglutide treatment compared with placebo were driven primarily by shifts in the domains of mobility and self-care.
    2 context sentences
    Summary · context
    The EQ-5D was administered every 12 months in a subset of patients from Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, the United Kingdom and the United States.
    Summary · context
    We compared changes in utility index scores and visual analogue scale (VAS) scores from baseline to 36 months in participants treated with liraglutide and placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.